PT3267983T - Métodos para o tratamento de proteinopatias - Google Patents
Métodos para o tratamento de proteinopatiasInfo
- Publication number
- PT3267983T PT3267983T PT167110881T PT16711088T PT3267983T PT 3267983 T PT3267983 T PT 3267983T PT 167110881 T PT167110881 T PT 167110881T PT 16711088 T PT16711088 T PT 16711088T PT 3267983 T PT3267983 T PT 3267983T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- treating proteinopathies
- proteinopathies
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131071P | 2015-03-10 | 2015-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3267983T true PT3267983T (pt) | 2024-03-12 |
Family
ID=55587378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167110881T PT3267983T (pt) | 2015-03-10 | 2016-03-09 | Métodos para o tratamento de proteinopatias |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20180036295A1 (enExample) |
| EP (2) | EP3267983B1 (enExample) |
| JP (2) | JP6990110B2 (enExample) |
| KR (1) | KR20170123329A (enExample) |
| CN (1) | CN107872976A (enExample) |
| AU (1) | AU2016229826A1 (enExample) |
| CA (1) | CA2978883A1 (enExample) |
| EA (1) | EA201791993A1 (enExample) |
| ES (1) | ES2973101T3 (enExample) |
| HK (1) | HK1244217A1 (enExample) |
| HU (1) | HUE065628T2 (enExample) |
| IL (1) | IL254393A0 (enExample) |
| MX (1) | MX2017011598A (enExample) |
| PL (1) | PL3267983T3 (enExample) |
| PT (1) | PT3267983T (enExample) |
| TW (1) | TW201642855A (enExample) |
| WO (1) | WO2016145046A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| BR112019027029A2 (pt) * | 2017-06-19 | 2020-07-14 | Kainos Medicine, Inc. | moduladores de alfa-sinucleina |
| TWI644673B (zh) * | 2017-07-27 | 2018-12-21 | 百朗克股份有限公司 | 頭孢曲松的用途 |
| JP7633169B2 (ja) * | 2019-02-04 | 2025-02-19 | ジェンザイム・コーポレーション | グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置 |
| JP7511567B2 (ja) * | 2019-02-04 | 2024-07-05 | ジェンザイム・コーポレーション | リソソーム蓄積性疾患と関連する症状および障害を処置するための方法 |
| ES2984255T3 (es) * | 2019-11-15 | 2024-10-29 | Yuhan Corp | Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos |
| US12083115B2 (en) * | 2020-02-03 | 2024-09-10 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| JP7637121B2 (ja) * | 2020-03-17 | 2025-02-27 | 住友ファーマ株式会社 | オキサジアゾール誘導体 |
| CN115715189A (zh) * | 2020-03-23 | 2023-02-24 | 普拉西斯精密医药公司 | Kcnt1抑制剂和使用方法 |
| BR112023000798A2 (pt) * | 2020-07-24 | 2023-02-07 | Genzyme Corp | Composições farmacêuticas compreendendo venglustat |
| CA3187086A1 (en) * | 2020-07-30 | 2022-02-03 | Tanya Zaremba FISCHER | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| AU2023403087A1 (en) | 2022-12-01 | 2025-07-17 | Genzyme Corporation | Venglustat in combination with a strong or moderate inhibitor of cyp3a4 |
| WO2025262570A1 (en) | 2024-06-17 | 2025-12-26 | Genzyme Corporation | Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683A (en) | 1846-08-08 | waring and richard e | ||
| US195A (en) | 1837-05-15 | Machine fob cutting and dressing stone | ||
| BE640616A (enExample) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| PT2685986T (pt) * | 2011-03-18 | 2020-03-05 | Genzyme Corp | Inibidor de glicosilceramida-sintase |
| CA2840224C (en) * | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
-
2016
- 2016-03-08 TW TW105107080A patent/TW201642855A/zh unknown
- 2016-03-09 WO PCT/US2016/021512 patent/WO2016145046A1/en not_active Ceased
- 2016-03-09 CA CA2978883A patent/CA2978883A1/en not_active Abandoned
- 2016-03-09 ES ES16711088T patent/ES2973101T3/es active Active
- 2016-03-09 PT PT167110881T patent/PT3267983T/pt unknown
- 2016-03-09 US US15/556,444 patent/US20180036295A1/en not_active Abandoned
- 2016-03-09 PL PL16711088.1T patent/PL3267983T3/pl unknown
- 2016-03-09 CN CN201680026839.XA patent/CN107872976A/zh active Pending
- 2016-03-09 MX MX2017011598A patent/MX2017011598A/es unknown
- 2016-03-09 EA EA201791993A patent/EA201791993A1/ru unknown
- 2016-03-09 HU HUE16711088A patent/HUE065628T2/hu unknown
- 2016-03-09 AU AU2016229826A patent/AU2016229826A1/en not_active Abandoned
- 2016-03-09 EP EP16711088.1A patent/EP3267983B1/en active Active
- 2016-03-09 HK HK18103748.9A patent/HK1244217A1/zh unknown
- 2016-03-09 JP JP2017547448A patent/JP6990110B2/ja active Active
- 2016-03-09 KR KR1020177027604A patent/KR20170123329A/ko not_active Withdrawn
- 2016-03-09 EP EP23217745.1A patent/EP4349408A3/en active Pending
-
2017
- 2017-09-10 IL IL254393A patent/IL254393A0/en unknown
-
2020
- 2020-03-02 US US16/807,102 patent/US20200197374A1/en active Pending
-
2021
- 2021-05-06 JP JP2021078459A patent/JP7374149B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL254393A0 (en) | 2017-11-30 |
| JP2021119185A (ja) | 2021-08-12 |
| WO2016145046A1 (en) | 2016-09-15 |
| JP2018507886A (ja) | 2018-03-22 |
| PL3267983T3 (pl) | 2024-05-13 |
| KR20170123329A (ko) | 2017-11-07 |
| JP7374149B2 (ja) | 2023-11-06 |
| JP6990110B2 (ja) | 2022-02-10 |
| CA2978883A1 (en) | 2016-09-15 |
| TW201642855A (zh) | 2016-12-16 |
| US20180036295A1 (en) | 2018-02-08 |
| EP4349408A2 (en) | 2024-04-10 |
| HUE065628T2 (hu) | 2024-06-28 |
| AU2016229826A1 (en) | 2017-10-26 |
| ES2973101T3 (es) | 2024-06-18 |
| MX2017011598A (es) | 2017-12-20 |
| US20200197374A1 (en) | 2020-06-25 |
| EA201791993A1 (ru) | 2017-12-29 |
| CN107872976A (zh) | 2018-04-03 |
| EP3267983A1 (en) | 2018-01-17 |
| HK1244217A1 (zh) | 2018-08-03 |
| EP4349408A3 (en) | 2024-06-19 |
| EP3267983B1 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298497B1 (en) | A method for treating cancer | |
| IL304252A (en) | Cancer treatment methods | |
| IL289947A (en) | A method for treating cancer | |
| IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
| ZA201705673B (en) | Methods for treating skin | |
| SG11201708861VA (en) | Methods for treating cancer | |
| GB201502645D0 (en) | Method | |
| IL254393A0 (en) | Methods for treating diseases associated with pathological changes in protein | |
| IL257691A (en) | A method for treating cancer | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| IL258988A (en) | Methods for treating epilepsy | |
| IL255022A0 (en) | Cancer treatment methods | |
| GB201500427D0 (en) | Method | |
| IL249936A0 (en) | Methods for treating hypotension | |
| SG11201605070UA (en) | Novel methods for treating cancer | |
| IL255018A0 (en) | Cancer treatment methods | |
| SG10201508795XA (en) | Method for treating cancer | |
| GB201501565D0 (en) | Method | |
| IL255016A0 (en) | Cancer treatment methods | |
| PT3250218T (pt) | Péptido natkide para o tratamento da obesidade | |
| ZA201607068B (en) | Methods for treating hypersomnia | |
| SG11201706885RA (en) | Novel treatment method | |
| GB201502409D0 (en) | Method | |
| IL249616A0 (en) | Methods for treating inflammation | |
| GB201520426D0 (en) | Improved method |